Immunotherapy in MSI/dMMR Tumors in Perioperative Setting
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms IMHOTEP
- 27 Jun 2024 Planned number of patients changed from 160 to 240.
- 24 Jan 2024 Planned End Date changed from 1 Oct 2026 to 1 Oct 2029.
- 24 Jan 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2025.